Mr. Nader Saroufeem is a pharmacist who is specialized in Oncology in Astoria, New York. Patients can reach him at 3175 23rd St Ste 410, Astoria or contact him on 718-316-6814. Active license number of Mr. Nader Saroufeem is 050068 for Oncology in New York. Mr. Nader Saroufeem is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Mr. Nader Saroufeem speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mr. Nader Saroufeem
Specialization:
Oncology
Credentials:
R.PH.
Gender:
Male
Location:
3175 23rd St Ste 410, Astoria, New York, 11106-4134
Phone:
718-316-6814
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mr. Nader Saroufeem are as mentioned below.
NPI Number:
1023337334
NPI Enumeration Date:
26 May, 2010
NPI Last Update On:
24 Sep, 2010
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mr. Nader Saroufeem are as mentioned below.
Specialization
License Number
State
Status
Oncology
050068
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
3175 23rd St, Astoria, New York
Zip:
11106-4134
Phone Number:
718-297-9111
Fax Number:
--
Patients can reach Mr. Nader Saroufeem at 3175 23rd St Ste 410, Astoria, New York or can call on phone at 718-316-6814.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.